VC-backed human gene therapy specialist Amsterdam Molecular Therapeutics (AMT) has launched an offering of up to 5 million new shares, for a price range of EUR 8-10.
Vehicle is expected to hold a final close in March 2020, Unquote understands
Merger of German and Dutch peers will result in a client base of 3,500 companies
Fund's predecessor, BlackFin Financial Services Fund II, closed on €400m in 2016
GP will support the Munich-based software company's growth by broadening its product offering